Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.

JAMA neurology - 1 Jul 2013

Chahine Lama M, Qiang Judy, Ashbridge Emily, Minger James, Yearout Dora, Horn Stacy, Colcher Amy, Hurtig Howard I, Lee Virginia M-Y, Van Deerlin Vivianna M, Leverenz James B, Siderowf Andrew D, Trojanowski John Q, Zabetian Cyrus P, Chen-Plotkin Alice

Abstract excerpt

IMPORTANCE: Biochemical abnormalities present in GBA (mut/wt) carriers may offer new pathogenetic insights to and potential therapeutic targets in Parkinson disease (PD). OBJECTIVE: To determine whether patients having PD with vs without GBA mutations differ in clinical phenotype or plasma protei...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Age of Onset

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta-Glucosidase

Share to Blood Proteins

Share to Case-Control Studies

Share to Cohort Studies

Share to Parkinson Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 23699752
DOI: 10.1001/jamaneurol.2013.1274
PMCID: PMC3762458

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23699752-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.PMID 23699752Read ↗

Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach.Semantic proximity Read ↗

Transcriptome deregulation of peripheral monocytes in <i>GBA</i>-related Parkinson’s diseaseSemantic proximity Read ↗

Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson's disease.Semantic proximity Read ↗

A proteogenomic view of Parkinson’s disease causality and heterogeneitySemantic proximity Read ↗

Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease.Semantic proximity Read ↗

Parkinson’s disease causality and heterogeneity: a proteogenomic viewSemantic proximity Read ↗

Parkinson’s disease causality and heterogeneity: a proteogenomic viewSemantic proximity Read ↗

Plasma Cytokines Profile in Patients with Parkinson's Disease Associated with Mutations in GBA Gene.Semantic proximity Read ↗

Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson diseaseSemantic proximity Read ↗

Secretome Analyses Identify FKBP4 as a GBA1-Associated Protein in CSF and iPS Cells from Parkinson's Disease Patients with GBA1 Mutations.Semantic proximity Read ↗

Comparative Transcriptome Analysis in Monocyte-Derived Macrophages of Asymptomatic GBA Mutation Carriers and Patients with GBA-Associated Parkinson's Disease.Semantic proximity Read ↗

Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.